Thiazolidinediones—sometimes shortened to TZDs or glitazones—work on lowering your insulin resistance, which is the underlying problem for many people with type 2 diabetes.
Repaglinide and nateglinide were developed in 1997. They’re often grouped together, even though they’re technically part of two different classes of medications. Repaglinide is a meglitinide, and nateglinide is a phenylalanine derivative.